Harpoon Therapeutics Names Erbez as Chief Financial Officer
1 November 2018 - - US-based immunotherapy company Harpoon Therapeutics, Inc has appointed Georgia L. Erbez as chief financial officer, the company said.

Additionally, the company promoted Holger Wesche, PhD, from senior vice president, research to chief scientific officer.

Erbez previously served as chief business officer and chief financial officer of Zosano Pharma, a therapeutics company focused on migraine, from 2016 through 2018.

She also served as chief financial officer and executive vice president of Asterias Biotherapeutics and chief financial officer, secretary and treasurer of Raptor Pharmaceuticals, where she helped to navigate the company through a growth period that included its first drug approval and subsequent commercial launch.

Prior to Raptor, Erbez was a managing director, Healthcare Investment Banking at Collins Stewart, a Founder and Managing director at Beal Advisors, and a senior level investment banker at Jefferies and company, and Cowen and company. She has also held positions at the investment banks Hambrecht and Quist and Alex. Brown and Sons.

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases.